COVID-19: Get Vaccinated. Get Tested. Visitor Guidelines. Please use ER for Emergency Issues only.

Multiple Myeloma

 

  • EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma
  • EAA181 Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
  • S1803 Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma using minimal residual disease to direct therapy duration (DRAMMATIC Study)